2026-06-14T03:54:35Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/263252025-12-18T12:59:05Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16939col_20.500.12105_16962col_20.500.12105_16974col_20.500.12105_25179

00925njm 22002777a 4500 dc Calvo-Silveria, Sara author González-Díaz, Aida author Grau, Inmaculada author Marimón, José María author Cercenado, Emilia author Quesada, M Dolores author Casabella, Antonio author Larrosa, Nieves author Yuste, Jose Enrique author Berbel, Dàmaris author Alonso, Marta author Tubau, Fe author Belman, Sophie author Cadenas-Jiménez, Irene author Martin-Galiano, Antonio Javier author Domínguez, María Ángeles author Martí, Sara author Liñares, Josefina author Pallarés, Román author Càmara, Jordi author Ardanuy, Carmen author 2024-06 Background: Invasive pneumococcal disease due to serotype 3 (S3-IPD) is associated with high mortality rates and long-term adverse effects. The introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into the Spanish paediatric immunisation programme has not led to a decrease in the adult S3-IPD. We aimed to analyse the incidence, clinical characteristics and genomics of S3-IPD in adults in Spain. Methods: Adult IPD episodes hospitalized in a Southern Barcelona hospital were prospectively collected (1994-2020). For genomic comparison, S3-IPD isolates from six Spanish hospitals (2008-2020) and historical isolates (1989-1993) were analysed by WGS (Illumina and/or MinION). Findings: From 1994 to 2020, 270 S3-IPD episodes were detected. When comparing pre-PCV (1994-2001) and late-PCV13 (2016-2020) periods, only modest changes in S3-IPD were observed (from 1.58 to 1.28 episodes per 100,000 inhabitants year). In this period, the incidence of the two main lineages shifted from 0.38 to 0.67 (CC180-GPSC12) and from 1.18 to 0.55 (CC260-GPSC83). The overall 30-day mortality remained high (24.1%), though a decrease was observed between the pre-PCV (32.4%; 95.0% CI, 22.0-45.0) and the late-PCV13 period (16.7%; 95.0% CI, 7.5-32.0) (p = 0.06). At the same time, comorbidities increased from 77.3% (95.0% CI, 65.0-86.0) to 85.7% (95.0% CI, 71.0-94.0) (p = 0.69). There were no differences in clinical characteristics or 30-day mortality between the two S3 lineages. Although both lineages were genetically homogeneous, the CC180-GPSC12 lineage presented a higher SNP density, a more open pan-genome, and a major presence of prophages and mobile genetic elements carrying resistance genes. Interpretation: Adult S3-IPD remained stable in our area over the study period despite PCV13 introduction in children. However, a clonal shift was observed. The decrease in mortality rates and the increase in comorbidities suggest a change in clinical management and overall population characteristics. The low genetic variability and absence of clinical differences between lineages highlight the role of the S3 capsule in the disease severity. Calvo-Silveria S, González-Díaz A, Grau I, Marimón JM, Cercenado E, Quesada MD, Casabella A, Larrosa N, Yuste J, Berbel D, Alonso M, Tubau F, Belman S, Cadenas-Jiménez I, Martín-Galiano AJ, Domínguez MÁ, Martí S, Liñares J, Pallarés R, Càmara J, Ardanuy C. Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study. Lancet Reg Health Eur. 2024 May 3;41:100913. 10.1016/j.lanepe.2024.100913 2666-7762 The Lancet regional health. Europe. 38737571 https://hdl.handle.net/20.500.12105/26325 Genomics Serotype 3 Streptococcus pneumoniae Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study